These studies demonstrate that CCR2 expression is important in DCIS progression and identify CCL2/CCR2 as a regulator of SMAD3 and p42/44MAPK signaling in breast cancer cells. The gene discussed is CCR2; the disease is ductal breast carcinoma in situ.